SOUTH SAN FRANCISCO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial. The data from both trials will be presented at a poster session during the AACR-NCI -EORTC’s “Molecular Targets and Cancer Therapeutics” International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company’s lead product candidate.
In addition to the Phase 1 cardiac safety assessment and the Phase 2 trial in patients with colorectal cancer, Poniard is evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR trial in patients with small cell lung cancer, and in a Phase 2 clinical trial in patients with castration-resistant prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Poniard has received both Orphan Drug designation and Fast Track designation for picoplatin for the second-line treatment of refractory or resistant SCLC from the FDA and orphan medicinal product designation for the treatment of SCLC by the European Commission.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
CONTACT: Investors, Rebecca Birbach of Burns McClellan, +1-212-213-0006,
rbirbach@burnsmc.com, or Susan Neath of WeissComm Partners,
+1-609-529-0676, sneath@wcpglobal.com; Media, Jani Bergan of WeissComm
Partners, +1-415-946-1064, jbergan@wcpglobal.com; all for Poniard
Pharmaceuticals, Inc.
Web site: http://www.poniard.com/
